WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 601124
CAS#: 247068-85-5 (CFLZ-171 TFA salt)
Description: CFLZ-171 is a key intermediate for making carfilzomib.
MedKoo Cat#: 601124
Name: CFLZ-171 TFA salt
CAS#: 247068-85-5 (CFLZ-171 TFA salt)
Chemical Formula: C9H17NO2
Exact Mass: 171.12593
Molecular Weight: 171.24
Elemental Analysis: C, 63.13; H, 10.01; N, 8.18; O, 18.69
CFLZ-171 TFA salt is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Synonym: carfilzomib intermediate molecule weight 171. 1Pentanone 2amino4methyl1(2R)2methyl2oxiranyl (2S) 222trifluoroacetate (1:1); 1Pentanone 2amino4methyl1(2R)2methyloxiranyl (2S) trifluoroacetate (9CI).
IUPAC/Chemical Name: (S)-2-amino-4-methyl-1-((R)-2-methyloxiran-2-yl)pentan-1-one 2,2,2-trifluoroacetate
InChi Key: OWGGQBZQMQMPBI-DKXTVVGFSA-N
InChi Code: InChI=1S/C9H17NO2.C2HF3O2/c1-6(2)4-7(10)8(11)9(3)5-12-9;3-2(4,5)1(6)7/h6-7H,4-5,10H2,1-3H3;(H,6,7)/t7-,9+;/m0./s1
SMILES Code: CC(C)C[C@H](N)C([C@]1(C)OC1)=O.O=C(O)C(F)(F)F
The following data is based on the product molecular weight 171.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Kim KB, Crews CM. From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes. Nat Prod Rep. 2013 May;30(5):600-4. doi: 10.1039/c3np20126k. Review. PubMed PMID: 23575525; PubMed Central PMCID: PMC3815659.
2: Kortuem KM, Stewart AK. Carfilzomib. Blood. 2013 Feb 7;121(6):893-7. doi: 10.1182/blood-2012-10-459883. Review. PubMed PMID: 23393020.
3: Thompson JL. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Ann Pharmacother. 2013 Jan;47(1):56-62. doi: 10.1345/aph.1R561. Epub 2013 Jan 8. Review. PubMed PMID: 23300152.
4: Carfilzomib (Kryprolis) for multiple myeloma. Med Lett Drugs Ther. 2012 Dec 24;54(1406):103-4. Review. PubMed PMID: 23282792.
5: McCormack PL. Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma. Drugs. 2012 Oct 22;72(15):2023-32. doi: 10.2165/11209010-000000000-00000. Review. PubMed PMID: 22994535.
6: Kuhn DJ, Orlowski RZ, Bjorklund CC. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets. 2011 Mar;11(3):285-95. Review. PubMed PMID: 21247387.
Related:
247068-85-5 (CFLZ-171 TFA salt)
1140908-93-5 (CFLZ-171 formic acid salt)
247068-84-4 (CFLZ-171 free base).
Carfilzomib intermediates (CFLZ-171 and CFLZ-567) are key intermeidates for making Carfilzomib. The reaction is shown as the following: